Note: Descriptions are shown in the official language in which they were submitted.
BONE-STRENGTHENING PILL (BSP) AS A DIETARY SUPPLEMENT TO
IMPROVE BLOOD CIRCULATION AND STRENGTHEN BONE AND MUSCLE
FIELD OF THE INVENTION
[0001] The present invention relates to a dietary supplement which is made
from plants as
the main raw materials and has the functions of promoting blood circulation,
invigorating
health, repairing body damage, especially improving human microcirculation,
preventing
and repairing degeneration to bone & cartilage tissue and muscle tissue.
DESCRIPTION OF THE RELATED ART
[0002] Blood circulation is the basis for the energy supplement and metabolism
of a human
body, and a variety of diseases will occur in case of poor blood circulation.
Microcirculation,
in particular, replenishes the body's material needs through the exchange of
substances
between blood and tissue fluids. Under normal circumstances, the blood flow of
microcirculation is adapted to the metabolic level of tissues and organs,
which can ensure
the blood flow of tissues and organs and regulate the amount of blood
returning to heart. If
a microcirculation disorder occurs, it will directly affect the physiological
functions of
various organs. Microcirculatory disorders can take place in many forms, but
more
common manifestations mainly include physical weakness and decay of muscle or
bone
tissue. Among them, physical weakness is mostly manifested as general malaise,
shoitness
of breath, atony, action difficulty, insomnia, irritability, frequent colds,
etc., and is mostly
accompanied by various degenerative processes. The decay of muscle tissue is
often
manifested as muscle relaxation, frequent sores, unhealed trauma, etc. The
decay of bone
tissue is mostly manifested as osteoporosis, susceptibility to fracture,
chondritis,
osteomyelitis, bone tuberculosis, bone cyst and other kinds of inflammation,
especially the
weight-bearing parts such as femoral head, which are easily damaged or
necrotic due to
insufficient blood supply.
[0003] In the past, body decay caused by blood circulation disorders,
especially the
inflammation and injury of bone and muscle tissues, were treated in accordance
with
pathological changes, and medication or surgical treatment was often used. The
duration of
medication is long, with an uncertain curative effect. Many medicines should
not be taken
for a long time as they have toxic and side effects. Surgical treatment
usually results in
larger trauma, with a high cost, and mostly at the cost of local tissue and
function loss.
1
Date Recue/Date Received 2020-04-27
Therefore, it is best to prevent or repair the above symptom of body decay,
especially the
damage to bone tissue and muscle tissue, by dredging the blood flowing pathway
and
eliminating the microcirculation obstacle before or at the beginning of its
discovery.
Obviously, to achieve this, it is necessary to change the existing treatment
philosophy and
practice, and also to achieve the purpose of promoting blood circulation and
removing
blood stasis, preventing and repairing micro-obstacles through dietary
supplements in daily
life. Dietary supplements that can realize this purpose are scarce.
SUMMARY OF THE INVENTION
[0004] The purpose of the present invention is to provide a dietary supplement
which can
dredge blood circulation path, promote microcirculation, prevent or repair
microcirculation
disturbance, especially strengthen physique, improve and reverse degeneration
of bone and
cartilage tissue and muscle tissue, supplement the nutrients needed to
maintain body
movement, safeguard the health, normal metabolism and physiological function
of bones
and muscles, for a human body; and can be taken for a long time as it has no
toxic or side
effects.
[0005] The purpose above is achieved with the following technical scheme: a
Bone-
Strengthening Pill (BSP) as a dietary supplement to improve blood circulation,
strengthen
bone and muscle, and promote the degenerative damage of bone & cartilage and
muscle
diseases is provided, charicterized in that the dietary supplement is made
from the
following raw materials: Angelica Sinensis, Panax Notoginseng and Carthamus
Tinctorius
L.
[0006] The proportions (by weight) of the aforesaid raw materials are: 280-320
units of
Angelica Sinensis, 55-65 units of Panax Notoginseng, and 12-18 units of
Carthamus
Tinctorius L.
[0007] Lumbricus, Pearl and Borneol are added into the aforesaid raw
materials.
[0008] The proportions (by weight) of the additional materials are: 80-100
units of
Lumbricus, 2-5 units of Pearl and 2-5 units of Borneol.
[0009] Codonopsis Pilosula, Rhizoma Atractylodis and Platycodonopsis
Grandiflorum are
added into the aforesaid raw materials or the additional materials.
2
Date Recue/Date Received 2020-04-27
[0010] 180-220 units of Codonopsis Pilosula, 55-65 units of Rhizoma
Atractylodis, and 55-
65 units of Platycodonopsis Grandiflorum are added into the aforesaid raw
materials or the
additional materials by weight.
[0011] White Peony Root, Ligusticum Wallichii, Polygala Tenuifolia and
American
Ginseng are added into the aforesaid raw materials or the additional
materials.
[0012] 80-100 units of White Peony Root, 25-35 units of Ligusticum Wallichii,
25-35 units
of Polygala Tenuifolia and 2-5 units of American Ginseng are added into the
aforesaid raw
materials or the additional materials by weight.
[0013] Rhizoma Atractylodis Macrocephaiae, Coix Seed, Chinese Yam and
Pseudostellaria
Heterophylla are added into the aforesaid raw materials or the additional
materials.
[0014] 80-100 units of Rhizoma Atractylodis Macrocephaiae, 28-32 units of Coix
Seed,
28-32 units of Chinese Yam, and 2-5 units of Pseudostellaria Heterophylla are
added into
the aforesaid raw materials or the additional materials by weight.
[0015] Astragalus Membranaceus, Psoralen, Polygala Tenuifolia and Radix
Glycyrrhizae
are added into the aforesaid raw materials or the additional materials.
[0016] 80-100 units of Astragalus Membranaceus, 28-32 units of Psoralen, 28-32
units of
Polygala Tenuifolia and 2-5 units of Radix Glycyrrhizae are added into the
aforesaid raw
materials or the additional materials by weight.
[0017] Achyranthes Bidentata, Sealwort, White Peony Root and Eurycoma
Longifolia are
added into the aforesaid raw materials or the additional materials.
[0018] 28-32 units of Achyranthes Bidentata, 28-32 units of Sealwort, 80-100
units of
White Peony Root, and 2-5 units of Eurycoma Longifolia are added into the
aforesaid raw
materials or the additional materials by weight.
[0019] 80-100 units of Ligusticum Wallichii, 28-32 units of Prepared Rehmannia
Glutinosa,
28-32 units of Eucommia Ulmoides and 2-5 units of Rhodiola Rosea are added
into the
aforesaid raw materials or the additional materials by weight.
[0020] The beneficial effect of the invention is as follows: The dietary
supplement
described hereof has functions to promote blood circulation, dredge
microcirculation
3
Date Recue/Date Received 2020-04-27
disturbance, significantly improve the health level, improve blood running of
bone and
muscle tissue, prevent or repair microscopic damage to bone & cartilage and
muscle tissue
of a human body, etc., especially to obviously inhibit or reverse
osteoporosis, bone fiber
hyperplasia, bone necrosis, chondritis, nonunion, bone tuberculosis,
osteomyelitis, bone
trauma, osteoarthritis, rheumatoid arthritis, bone cyst and other refractory
injury, is non-
toxic and free of side effects, can be taken for a long term, and is suitable
for all kinds of
populations with weak physique, muscle or bone tissue with pathological signs
or
symptoms.
BRIEF DESCRIPTION OF THE DRAWINGS
[0021] FIG. 1 is an experimental image of Embodiment 1;
FIG. 2 is a NMR image of Embodiment 1;
FIG. 3 is a CT image of Embodiment 1;
FIG. 4 is an X-ray image of Embodiment 1;
FIG. 5 is an X-ray image of Embodiment 2;
FIG. 6 is an X-ray image of Embodiment 3;
FIG. 7 is an X-ray image of Embodiment 3;
FIG. 8 is a NMR image of Embodiment 4;
FIG. 9 is a NMR image of Embodiment 4;
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
[0022] Embodiment 1: to produce a dietary supplement that promotes blood
circulation and
improve bone and muscle. With the experiment name of Bone-Strengthening Pill
(BSP),
such dietary supplement is made from the following materials: Angelica
Sinensis, Panax
Notoginseng and Carthamus Tinctorius L. Some of the above mentioned
experiments are
for medicinal purposes, but still provide evidence and support for this
dietary supplement.
[0023] The aforesaid raw materials are described as follows:
[0024] Angelica Sinensis, Radix Angelicae Sinensis for Latin name, is a
perennial herb of
4
Date Recue/Date Received 2020-04-27
Family Umbelliferae. Its root is one of the most common traditional Chinese
medicines.
[0025] Panax Notoginseng, Panax pseudoginseng Wall. Var. Notoginseng (Burkill)
Hoo et
Tseng for Latin name, is a perennial herb in the Panax ginseng genus of Family
Araliaceae
of Order Umbellales. Its root is used as medicine. In this study, Panax
Notoginseng is
identified to have a role in improving microcirculation.
[0026] Carthamus Tinctorius L., Carthamus tinctorius L. for Latin name, with
aliases such
as Spinose Carthamus Tinctorius L., is a herbal plant of Genus Carthamus
Tinctorius L. of
Family Compositae, habitually used as traditional Chinese medicine. The study
mainly
utilizes Carthamus Tinctorius L.'s functions to promote blood circulation and
remove stasis,
and to dredge blood microcirculation pathway.
[0027] The proportions (by weight) of the aforesaid raw materials are: 280-320
units of
Angelica Sinensis, 55-65 units of Panax Notoginseng, and 12-18 units of
Carthamus
Tinctorius L..
[0028] The optimized proportions (by weight) of the aforesaid raw materials
are: 300 units
of Angelica Sinensis, 60 units of Panax Notoginseng, and 15 units of Carthamus
Tinctorius
L.
[0029] The dietary supplement mentioned hereof may be processed and taken in a
variety
of ways. This embodiment only gives two examples:
[0030] 1. All raw materials are powdered, screened with more 80 meshes, and
then made
into decoction, powder, pill, tablet or capsule. The usage is to orally take 4-
10g every time,
three times a day, for adults.
[0031] All raw materials are crushed, decocted in water, and made into
decoction or the
decoction is concentrated into decoction, powder, pill, tablet and capsule.
The usage is to
orally take 2-5g every time, three times a day, for adults.
[0032] Safety: The above raw materials are safe and non-toxic. The dosage of
this
embodiment is lower than the limit specified in the relevant classic medical
books, so it can
be completely identified as being safe. Nevertheless, standard animal
experiments and
clinical trials have been conducted in this study to prove that the above
compatibility of
medicines is safe. The following are the experimental results of three
applications:
Date Recue/Date Received 2020-04-27
[003311. Experiment of weak population: Weakness mainly refers to the physical
weakness,
body discomfort, weakness after illness, postpartum weakness, weakness,
shortness of
breath, difficulty in walking, insomnia and forgetfulness, etc. caused by poor
blood
circulation,
[0034] Since 2010, the multi-parameter microcirculation measuring instrument
has been
used to detect several physically weak persons for 16 indexes of three
categories, such as
loop morphology, blood flow state, and surrounding state of nail fold
microcirculation. The
dietary supplement was taken by those with abnormal indexes. It deemed as
recovery that
the indexes are improved, the degenerative symptoms disappear, and no
recurrence is
observed after one year of follow-up. Recovery number/Total number x 100% =
Recovery
rate
The experimental situations are shown as follows:
Total Number Recovery Number Recovery Average
Duration of
Microcirculation Index
(Person) (Person) Rate (%) Medication (Week)
Slight Abnormality 42 35 83.3 3
Moderate Abnormality 36 29 80.6 5
Severe Abnormality 32 22 68.8 8
[0035] It indicates that this product has a good repair and improvement effect
on a variety
of microcirculation disturbance.
[0036] II. Experiment of bone tissue injury:
[0037] 1. Animal Experiment: Bone density, osteometrics, fat deposition of
femoral head,
capillary distribution of femoral head and related biochemical indexes were
tested and
studied with the castrated rat model of osteoporosis and two-legged rat model
of ischemic
necrosis of femoral head to evaluate the effect on promoting osteocytes and
osteochondrocytes. The experimental results are summarized as follows.
[0038] ONFH was induced by prednisone in rats and the occurrence rate is 90%.
The
surface of the femoral head occurred injuries or defects (Table 1 A Model
control). 70% of
6
Date Recue/Date Received 2020-04-27
rats were recovered after taking this product (Table 1 A Experimental group)
(FIG. 1A-C).
The number of capillaries in the femoral head was reduced and the vessel
arcuate cup was
disappeared by prednisone. The experimental group was returned to normal after
taking
this product (FIG. 1K-m).
[0039] Table 1 A The occurrence rate of ONFH model and comparison after taking
this
product
Groups n Manifestation Occurrence Occurrence
types number rate %
Model control 10 A 4 40
B 5 50
C 1 10
Experimental 10 A 0 0
group
B 3 30
C 7 70
A: The surface of the femoral head occurred injuries or defects; B: Only
osteocytes,
chondrocytes and bone marrow cells were changed, and no changes were observed
on the
surface of the femoral head; C: The surface of the femoral head is smooth with
normal
osteocytes and chondrocytes.
[0040] After the inducement of prednisone, the bone cortex and the trabecular
bone of rats
were fractured and reduced, myelocyte occurred necrosis, the related
indicators of bone
histomorphometry were significantly reduced, femoral bone trabecula volume
(TBV), bone
trabecula width (MTPT), cortex of bone volume (CBV), osteoid seam width (MOs
W) were
significantly lower, lacuna proportion in empty osteocytes (Nocy) was
significantly
increased, bone mineralization rate (MAR) was significantly decreased. All the
indexes of
the experimental group were returned to normal after taking this product
(Table 1B & FIG.
D-G).
7
Date Recue/Date Received 2020-04-27
[0041] Table 1 B Effect on the bone measurement of the femoral head in model
rats
after taking this product ( X SD )
Groups n TBV% MTP TMAR MOSW
Normal control 10 61.80 3.38 **108.08 6.17** 1.26 0.15* * 1.63
0.11**
Model control 10 55.03 5.14 93.53 12.28 0.66 0.11 0.83 0.05
Experimental 10 63.73 6.44 **108.20 6.56** 1.06 0.17** 1.44 0.29**
group
Notes: compared with normal control: *P<0.01; compared with model control:
4P<0.01
[0042] Steroid hormones have been shown to cause ONFH fat accumulation. In the
experiment, the number of fat granulosa cells was significantly increased by
prednisone,
and the experimental group was returned to normal after taking this product
(Table 1C)
(FIG. 1H-J):
Table 1 C Effect on osteochondrocytes and osteocyte fat deposition of the
femoral head
after taking this product
Average of the test results s
Groups n
Fat deposition cell rate % P value
Normal control 10 4.74 3.11 <0.01
Model control 10 16.64 7.42 -
Experimental group 10 4.63 2.22 <0.01
[0043] In the evaluation of serological markers associated with bone
conversion, the level
of taluate-resistant acid phosphatase TRAP (a biomarker for bone absorption)
was
increased while the level of ALP (a biomarker for bone formation) was
decreased by
prednisone. In the experimental group, the above changes were reversed (Table
1D):
8
Date Recue/Date Received 2020-04-27
Table 1 D Effects on blood biochemistry of model rats after taking this
product
_
Test results X + S
Groups n
TRAP (B-L) ALP(U)
Normal control 10 2.08 0.24A 5.13 0.96
Model control 10 2.40 0.33 4.57 1.44
Experimental group 10 1.47 0.32* 6.55 1.34*
Notes: A compared with control group P<0.05 *compared with control group
P<0.01
[0044]The experimental results are shown in FIG. 1. In FIG. A, the femoral
head of the
normal rats has smooth surface and chondrocytes arranging in a columnar
manner; in FIG.
B, the femoral head of the model rats has surface necrosis and detachment,
collapse and
coloboma, and loses chondrocytes; in FIG. C, the rats with femoral head
necrosis were
treated with this product (treatment group) showed that femoral head has
smooth surface,
is free of coloboma, and recovered chondrocytes in columnar arrangement; in
FIG. D, the
model rats show crimpiness, disorder and fracture of bone trabecula; in FIG.
E, the model
rats show the focal necrosis of intramedullary cells of femoral head; in FIG.
F., the bone
trabecula is rich and morphology is normal in the treatment group; in FIG. G,
no necrosis
was observed in myeloid cells in the treatment group; in FIG. H, a small
number of fat
particles were attached to the chondrocyte surface of the normal rat; in FIG.
I, a large
number of fat particles were contained in the chondrocytes of femoral head of
the model
rats; in FIG. J, a small number of fat particles were observed in the femoral
head of the rats
in the experimental group; in FIG. K, the capillaries of femoral head of the
normal rats are
abundant, with clear edges and interweaving into a network to form an "arcuate
cup"; in
Fig. L, the capillaries inside the femoral head of the model rats were sparse
and the "arcuate
cup" disappeared; in FIG. M, the capillaries of the femoral head of the rats
in the treatment
group were significantly increased, with clear edges, and the "arcuate cup"
recovered.
[0045] The results showed that this product can increase the minimum bone
density (MBD),
trabecula bone volume (TBV), mean trabecular plate thickness (MTPT) and
cortical bone
9
Date Recue/Date Received 2020-04-27
volume (CBV) of the model rats; can significantly increase the mineral
appositional rate
(MAR) and mean osteoid seam width (MO SW) of the femoral head of the model
rats,
decrease the fat deposition of the femoral head and enrich capillary
distribution of femoral
head; and bone-related biochemical tests showed the increased alkaline
phosphatase (ALP)
and decreased taitiate-resistant acid phosphatase (TRAP). Conclusion: This
product can
significantly promote bone growth, increase bone density, restore bone
substance and blood
supply, inhibit and reverse necrotic osteoblasts and chondrocytes, repair bone
and cartilage,
and is conducive to the recovery of bone and joint diseases and free of any
toxic and side
effects.
[0046] 2. Population Trial: Since 2010, this dietary supplement has been taken
by many
volunteers who were diagnosed by public hospitals. If the bone tissue decay
was controlled
or repaired, and no recurrence was observed in the two-year follow-up, it was
deemed as
recovery. Recovery number/Total number x 100% = Recovery rate. The
experimental
conditions are shown as follows:
Total Number Recovery Recovery Average Duration of
Type
(Person) Number (Person) Rate (%) Medication
(Week)
Osteoporosis 32 27 84.4 20
Osteonecrosis 36 29 80.6 36
Nonunion of fracture 32 28 87.5 16
Fibrous dysplasia 30 26 86.7 34
Bone cyst 30 27 90.0 30
Chondritis 34 29 85.3 26
It indicates that this product has a good repair and improvement effect on
multiple types of
bone tissue decay.
[0047] Typical Case:
[0048] As shown in FIG. 2: A male patient, 37 years old, had been diagnosed
with bilateral
Date Recue/Date Received 2020-04-27
femoral head necrosis for 3 years, had slight collapse and walking
difficulties. He returned
to normal work after 12 months of treatment. Before treatment, his MRI image
showed
abnormal signals of bilateral femoral head, showing large irregularity and
uneven signals;
abnormal signals of the right femoral head accounted for about 80%, while
those of the left
for about 60% (A). After treatment, the outline signals of femoral head were
uniform, and
the abnormal signal area was significantly reduced (B).
[0049] As shown in FIG. 3: A male patient, 60 years old, had been diagnosed
with bilateral
femoral head necrosis for 5 years and was unable to walk. He was cured after
18 months
of treatment. Before treatment, his CT image showed that the density of the
right femoral
head increased unevenly and the necrotic area was about 60%; the left femoral
head had
fracture, collapse, uneven density and unclear shape, and the necrotic area
was about 90%
(2-1). After treatment, the density of the right femoral head was uniform and
the shape was
normal; the shape of the left femoral head was slightly flat, and the density
basically
returned to being normal (2-2).
[0050] III. Experiment of population with muscle tissue decay:
Muscle tissue decay refers to a variety of abnormalities of muscle tissue
caused by poor
blood circulation and, such as recurrent muscle sores, unhealed skin wounds,
osteomyelitis,
and unhealed bone tuberculosis fistula or sinus tract, degenerative arthritis
and rheumatoid
arthritis.
[0051] Since 2010, this dietary supplement has been taken by many volunteers
who were
diagnosed by public hospitals. If the bone tissue decay was controlled or
repaired, and no
recurrence was observed in the one-year follow-up, it was deemed as recovery.
Recovery
number/Total number x 100% = Recovery rate.
[0052] The experimental results are shown as follows:
Total Number Recovery Number Recovery Rate Average Duration of
Type
(Person) (Person) (%) Treatment (Week)
Recurrent sores 34 27 79.4 16
Unhealed 36 30 83.3 15
11
Date Recue/Date Received 2020-04-27
wounds
Unhealed fistula
36 31 86.1 26
and fistulous tract
Degenerative
30 24 80.0 24
arthritis
Rheumatoid
36 23 63.9 36
arthritis
It indicates that this product has a good repair and improvement effect on
various types of
muscle tissue decay.
[0053] Typical Case: As shown in FIG. 4, a male patient, 36 years old, had
been diagnosed
with left femoral osteomyelitis for 12 years and undergone 3 fractures and 6
surgeries
successively. All the upper and middle section of the femur had skin
ulceration, exudation,
and necrosis, and unhealed fistulous tract. Once pus flowed, he had to lie in
bed. The
hospital told him to have an amputation. After 7 months of medication, his
skin returned to
being normal, his dead bone disappeared, his fistulous tract was healed, and
he returned to
work.
[0054] V. Bone density experiment in the general population: in the process of
vast
medical experiments, it was found that this product is suitable for the
general population as
a dietary supplement, which can be taken for a long time to significantly
improve the
decline of bone density, physical quality, insomnia, forgetfulness, back pain
and other
common signs of decline in the middle-aged and elderly population. Due to the
typical
significance of the changes in bone density, a number of comparative
experiments have
been conducted since 2017. Here is an experimental example:
[0055] On a voluntary basis, 60 subjects with ages between 50 and 65 were
collected and
all had the bone density test in a standard hospital with T values between -
2.5 -- -1, all of
them were mildly low bone density. Among them, 30 patients in the experimental
group
took orally 4-6g of this product, three times a day. In the control group, 30
people were
given calcium carbonate tablets, 1-2g per day. After continuous use for 6
months, recovery
referred to the T value was increased between -1 and 1, maintaining referred
to the T value
12
Date Recue/Date Received 2020-04-27
did not change, and invalid result referred to the T value was further
reduced. The results
are as follows:
Types n (subjects) Recovery Maintaining Invalid
Control group 30 12 10 8
Experimental group 30 19 9 2
The above experimental results show that the effect of this product is
relatively significant.
Especially in the experimental group, the diet, sleep and defecation of the
subjects are in
good physical conditions, and they are required to continuously take it. The
comprehensive
evaluation is significantly better than that in the control group, so as to
support the transition
of this product from drugs to dietary supplements.
[0056] Embodiment 2: Lumbricus, Pearl and Bomeol were added into the raw
materials
mentioned in Embodiment 1 to form a reinforced formula, with 280-320 units of
Angelica
Sinensis, 55-65 units of Panax Notoginseng, 12-18 units of Carthamus
Tinctorius L., 80-
100 units of Lumbricus, 2-5 units of Pearl and 2-5 units of Borneol. 300 units
of Angelica
Sinensis, 60 units of Panax Notoginseng, 15 units of Carthamus Tinctorius L.,
90 units of
Lumbricus, 3 units of Pearl and 3 units of Bomeol are preferred.
[0057] Introduction to newly added raw materials:
[0058] Lumbricus also known as Earthworm, is a representative animal in Class
Oligochaeta in Phylum Annelida and one of the important traditional Chinese
medicinal
materials. It is a nutrient source integrating protein, vitamins, minerals
and enzymes.
[0059] Peal (Pemulo) is a shiny particle formed in pearl sacs of several
pearly shellfishes.
It is a nutrient source integrating minerals, amino acids and nutrients.
[0060] Bomeol, a natural crystalline compound precipitated from the resin of
Kapur trees
of Dipterocarpaceae plants.
[0061] The processing and taking methods, safety, and experimental method of
the bone-
strengthening pill (BSP) as a dietary supplement are the same as those of
Embodiment 1:
13
Date Recue/Date Received 2020-04-27
The following are the experimental results of three applications:
[0062] I. The experimental situations of the weak population are as follows:
Total Number Recovery Recovery Average Duration of
Microcirculation Index
(Person) Number (Person) Rate (%) Medication (Week)
Slight Abnormality 46 40 87.0 3
Moderate Abnormality 36 30 83.3 5
Severe Abnormality 32 25 78.1 8
It indicates that this product has a good repair and improvement effect on a
variety of
microcirculation disturbance.
[0063] II. The experimental results of the population with bone tissue injury
are shown in
the following table:
Recovery
Total Number Recovery Average Duration of
Type Number
(Person) Rate (%) Medication (Week)
(Person)
Osteoporosis 36 31 86.1 18
Osteonecrosis 34 29 85.3 32
Nonunion of
30 27 90.0 14
fracture
Fibrous dysplasia 32 28 87.5 32
Bone cyst 36 32 88.9 30
Chondritis 30 26 86.7 25
It indicates that this product has a good repair and improvement effect on
multiple types of
bone tissue decay, which is superior to that of Embodiment 1.
14
Date Recue/Date Received 2020-04-27
[0064] Typical Case:
[0065] As shown in FIG. 5, a 29-year-old male patient had alcoholism. Before
administration, his femoral head had collapsed and deformation and uneven
density, and
the trabecular bone disappeared (A). There was a significant improvement after
treatment
(B). After administration, the femoral head looked the same as before, but
bone density was
uniform, and the patient returned to work (C).
[0066] III. The experimental results of the population with muscle tissue
decay are shown
in the following table:
Recovery Overall Response
Total Number Average Duration of
Type Number Rate (ORR)
(Person) Medication (Week)
(Person) (%)
Recurrent sores 38 32 84.2 14
Unhealed wounds 32 29 90.6 14
Unhealed fistula
36 33 91.7 24
and fistulous tract
Degenerative
32 28 87.5 22
arthritis
Rheumatoid
36 24 66.7 34
arthritis
It indicates that this product has a good repair and improvement effect on
various types of
muscle tissue decay.
[0067] IV . Bone density experiment in the general population: in the process
of vast
medical experiments, it was found that this product is suitable for the
general population as
a dietary supplement, which can be taken for a long time to significantly
improve the
decline of bone density, physical quality, insomnia, forgetfulness, back pain
and other
common signs of decline in the middle-aged and elderly population. Due to the
typical
significance of the changes in bone density, a number of comparative
experiments have
Date Recue/Date Received 2020-04-27
been conducted since 2017. Here is an experimental example:
[0068] On a voluntary basis, 60 subjects with ages between 50 and 65 were
collected and
all had the bone density test in a standard hospital with T values between -
2.5 -- -1, all of
them were mildly low bone density. Among them, 30 patients in the experimental
group
took orally 4-6g of this product, three times a day. In the control group, 30
people were
given calcium carbonate tablets, 1-2g per day. After continuous use for 6
months, recovery
referred to the T value was increased between -1 and 1, maintaining referred
to the T value
did not change, and invalid result referred to the T value was further
reduced. The results
are as follows:
Types n (subjects) Recovery Maintaining Invalid
Control group 30 13 8 9
Experimental group 30 21 8 1
The above experimental results show that the effect of this product is
relatively significant.
Especially in the experimental group, the diet, sleep and defecation of the
subjects are in
good physical conditions, and they are required to continuously take it. The
comprehensive
evaluation is significantly better than that in the control group, so as to
support the transition
of this product from drugs to dietary supplements.
[0069] Embodiment 3: Codonopsis Pilosula, Rhizoma Atractylodis and
Platycodonopsis
Grandiflorum are added into the raw materials mentioned in Embodiment 1 to
form a
reinforced formula, with 280-320 units of Angelica Sinensis, 55-65 units of
Panax
Notoginseng, 12-18 units of Carthamus Tinctorius L., 180-220 units of
Codonopsis
Pilosula, 55-65 units of Rhizoma Atractylodis, and 55-65 units of
Platycodonopsis
Grandiflorum. 300 units of Angelica Sinensis, 60 units of Panax Notoginseng,
15 units of
Carthamus Tinctorius L., 200 units of Codonopsis Pilosula, 60 units of Rhizoma
Atractylodis, and 60 units of Platycodonopsis Grandiflorum are preferred.
[0070] Introduction to newly added raw materials:
Codonopsis Pilosula (Codonopsis pilosula (Franch.) Nannf. for scientific
name), is a
perennial herb of Genus Codonopsis of Family Campanulaceae.
16
Date Recue/Date Received 2020-04-27
[0071] Rhizoma Atractylodis (Atractylodes Lancea (Thunb.) DC. for scientific
name) is a
perennial herb of Genus Atractylodes of Family Compositae.
[0072] Platycodonopsis Grandiflorum (Platycodon grandiflorus for scientific
name), with
alias such as Package Flower, Bell Flower and Mitral Flower, is a perennial
herb whose
root can be used as medicine.
[0073] The processing and taking methods, safety, and experimental method of
the dietary
supplement described herein are the same as those of Embodiment 1:
The following are the experimental results of three applications:
[0074] I. The experimental situations of the weak population are as follows:
Total
Microcirculation Recovery Number Recovery Average Duration
of
Number
Index (Person) Rate (%) Medication (Week)
(Person)
Slight Abnormality 44 40 90.9 3
Moderate
36 31 86.1 5
Abnormality
Severe Abnormality 34 29 85.3 8
It indicates that this product has a good repair and improvement effect on a
variety of
microcirculation disturbance.
[0075] II. The experimental results of the population with bone tissue injury
are shown in
the following table:
Recovery
Total Number Recovery Average Duration of
Type Number
(Person) Rate (%) Medication (Week)
(Person)
Osteoporosis 32 28 87.5 17
17
Date Recue/Date Received 2020-04-27
Osteonecrosis 32 27 84.4 30
Nonunion of
32 29 90.6 13
fracture
Fibrous dysplasia 34 29 85.3 30
Bone cyst 32 28 87.5 29
Chondritis 33 29 87.9 25
It indicates that this product has a good repair and improvement effect on
multiple types of
bone tissue decay.
[0076] Typical Case:
[0077] As shown in FIG.6, a female patient, 9 years old, has been sick for 2
years and
recovered after 16 months of administration . Before administration, her
femoral head had
coarse surface, increased density, uneven density and epiphyseal density (a).
After 7 months
of administration, her femoral head had unclear boundaries, decreased density,
and uniform
epiphyseal density (b). After administration, her femoral head was slightly
flat and had
smooth surface, clear trabecular bone and uniform density (c).
[0078] As shown in FIG. 7, a patient, 45 years old, had a large area of
decreased density on
the right side according to the X-ray image, and recovered after taking the
medicine.
[0079] III. The experimental results of the population with muscle tissue
decay are shown
in the following table:
Recovery Overall Response
Total Number Average Duration of
Type Number Rate (ORR)
(Person) Medication (Week)
(Person) C%)
Recurrent sores 32 28 87.5 14
Unhealed wounds 36 34 94.4 14
18
Date Recue/Date Received 2020-04-27
Unhealed fistula
32 30 93.8 22
and fistulous tract
Degenerative
34 29 85.3 22
arthritis
Rheumatoid
36 25 69.4 32
arthritis
It indicates that this product has a good repair and improvement effect on
various types of
muscle tissue decay, which is superior to that of Embodiment 1.
[0080] IV. Bone density experiment in the general population:
[0081] On a voluntary basis, 60 subjects with ages between 50 and 65 were
collected and
all had the bone density test in a standard hospital with T values between -
2.5 -- -1, all of
them were mildly low bone density. Among them, 30 patients in the experimental
group
took orally 4-6g of this product, three times a day. In the control group, 30
people were
given calcium carbonate tablets, 1-2g per day. After continuous use for 6
months, recovery
referred to the T value was increased between -1 and 1, maintaining referred
to the T value
did not change, and invalid result referred to the T value was further
reduced.
The results are as follows:
Types n ( subjects) Recovery Maintaining
Invalid
Control group 30 11 11 8
Experimental group 30 20 9 0
The above experimental results show that the effect of this product is
relatively significant.
Especially in the experimental group, the diet, sleep and defecation of the
subjects are in
good physical conditions, and they are required to continuously take it. The
comprehensive
evaluation is significantly better than that in the control group, so as to
support the transition
of this product from drugs to dietary supplements.
[0082] Embodiment 4: Lumbricus, Pearl, Borneol, Codonopsis Pilosula, Rhizoma
19
Date Recue/Date Received 2020-04-27
Atractylodis and Platycodonopsis Grandiflorum are added into the raw materials
mentioned
in Embodiment 1 to form a reinforced formula, with 280-320 units of Angelica
Sinensis,
55-65 units of Panax Notoginseng, 12-18 units of Carthamus Tinctorius L., 80-
100 units of
Lumbricus, 2-5 units of Pearl, 2-5 units of Borneol, 180-220 units of
Codonopsis Pilosula,
55-65 units of Rhizoma Atractylodis, and 55-65 units of Platycodonopsis
Grandiflorum.
[0083] The optimal proportions (by weight) of the raw materials are as
follows: 300 units
of Angelica Sinensis, 60 units of Panax Notoginseng, 15 units of Carthamus
Tinctorius L.,
90 units of Lumbricus, 3 units of Pearl, 3 units of B orneol, 200 units of
Codonopsis Pilosula,
60 units of Rhizoma Atractylodis, and 60 units of Platycodonopsis
Grandiflorum.
[0084] The processing method of the dietary supplement mentioned herein is to
powder all
raw materials, screen the powder with more 80 meshes, and then made into
decoction,
powder, pill, tablet or capsule.
[0085] The usage of the dietary supplement is to orally take 5-12g every time,
three times
a day, for adults.
[0086] The processing method of the dietary supplement mentioned herein is to
crush all
raw materials, decoct them in water, and make into decoction or concentrate
the decoction
into decoction, powder, pill, tablet or capsule.
[0087] The usage of the dietary supplement is to orally take 3-6g every time,
three times a
day, for adults.
The experimental method is the same as that Embodiment 1. The following are
the
experimental results of three applications:
[0088] I. The experimental situations of the weak population are as follows:
Total Recovery Overall Average Duration
Microcirculation
Number Number Response Rate of Medication
Index
(Person) (Person) (ORR) (%) (Week)
Slight Abnormality 43 40 93.0 3
33 29 87.9 5
Moderate
Date Recue/Date Received 2020-04-27
Abnormality
Severe Abnormality 36 31 86.1 8
It indicates that this product has a good repair and improvement effect on a
variety of
microcirculation disturbance.
[0089] II. The experimental results of the population with bone tissue injury
are shown in
the following table:
Recovery
Total Number Recovery Average Duration of
Type Number
(Person) Rate (%) Medication (Week)
(Person)
Osteoporosis 34 30 88.2 16
Osteonecrosis 36 32 88.9 30
Nonunion of
32 30 93.8 12
fracture
Fibrous dysplasia 36 32 88.9 28
Bone cyst 36 33 91.7 27
Chondritis 30 27 90.0 20
It indicates that this product has a good repair and improvement effect on
multiple types of
bone tissue decay.
[0090] Typical Case:
[0091] As shown in FIG. 8, a patient, 59 years old, had the decreased signal
on the right
femoral head and double-line signs (A-C) before treatment. The signal returned
to normal
after treatment (D-F).
[0092] As shown in FIG. 9, a patient, 38 years old, had lumbar sprain,
vertebral cartilage
avulsion, intervertebral disc herniation, and low back pain with pain in both
lower limbs,
21
Date Recue/Date Received 2020-04-27
and was unable to get out of bed or move. He was cured after three months of
treatment.
Before treatment, the MRI image showed fracture and degeneration of the
intervertebral
cartilage plates of the lumbar spines #4 and 35, vertebral body avulsion at
the ligamentous
attachment, intervertebral disc protrusion to the spinal canal, and obvious
compression of
the nerves in the spinal canal (A). After treatment, the avulsed
intervertebral cartilage plate
and vertebral body were repaired, and the intervertebral nerve compression and
cutting
disappeared (B).
[0093] III. The experimental results of the population with muscle tissue
decay are shown
in the following table:
Recovery
Total Number Recovery Rate Average Duration of
Type Number
(Person) (%) Medication (Week)
(Person)
Recurrent sores 36 33 91.7 13
Unhealed wounds 38 36 94.7 12
Unhealed fistula
32 30 93.8 20
and fistulous tract
Degenerative
30 27 90.0 20
arthritis
Rheumatoid
36 26 72.2 30
arthritis
It indicates that this product has a good repair and improvement effect on
various types of
muscle tissue decay.
[0094] IV. Bone density experiment in the general population:
[0095] On a voluntary basis, 60 subjects with ages between 50 and 65 were
collected and
all had the bone density test in a standard hospital with T values between -
2.5 -- -1, all of
them were mildly low bone density. Among them, 30 patients in the experimental
group
took orally 4-6g of this product, three times a day. In the control group, 30
people were
22
Date Recue/Date Received 2020-04-27
given calcium carbonate tablets, 1-2g per day. After continuous use for 6
months, recovery
referred to the T value was increased between -1 and 1, maintaining referred
to the T value
did not change, and invalid result referred to the T value was further
reduced. The results
are as follows:
Types n ( subjects) Recovery Maintaining
Invalid
Control group 30 12 10 8
Experimental group 30 22 8 0
The above experimental results show that the effect of this product is
relatively significant.
Especially in the experimental group, the diet, sleep and defecation of the
subjects are in
good physical conditions, and they are required to continuously take it. The
comprehensive
evaluation is significantly better than that in the control group, so as to
support the transition
of this product from drugs to dietary supplements.
[0096] Embodiment 5: White Peony Root, Ligusticum Wallichii, Polygala
Tenuifolia and
American Ginseng are added into the raw materials Angelica Sinensis, Panax
Notoginseng
and Carthamus Tinctorius L. to form a reinforced formula, with 280-320 units
of Angelica
Sinensis, 55-65 units of Panax Notoginseng, 12-18 units of Carthamus
Tinctorius L., 80-
100 units of White Peony Root, 25-35 units of Ligusticum Wallichii, 25-35
units of
Polygala Tenuifolia and 2-5 units of American Ginseng.
[0097] 300 units of Angelica Sinensis, 60 units of Panax Notoginseng, 15 units
of
Carthamus Tinctorius L., 90 units of White Peony Root, 30 units of Ligusticum
Wallichii,
30 units of Polygala Tenuifolia and 3 units of American Ginseng are preferred.
[0098] Introduction to newly added raw materials:
[0099] White Peony Root is dry root of Paeonia tactilora Pall. , a
Ranunculaceae plant.
[0100] Ligusticum Wallichii (Scientific name:Ligusticum chuanxiong hort) is a
herbal
plant for traditional Chinese medicine.
[0101] Polygala Tenuifolia (Scientific name: Polygala tenuifolia Willd), also
known as Fine
Grass and Line Tea, is a perennial herb. Traditional Chinese medicine believes
that Polygala
23
Date Recue/Date Received 2020-04-27
Tenuifolia has the functions of tranquilizing mind, promoting intelligence,
and relieving
sputum and swelling. This application is based on the close relationship
between human
microcirculation and e regulation of thnervous system, so Polygala Tenuifolia
is used.
[0102] American Ginseng (Scientific name: Panax quinquefolius) is a perennial
plant of
Genus Panax of Family Araliaceae.
[0103] The processing and taking methods, safety and experimental method of
the dietary
supplement mentioned herein are the same as those of Embodiment 4.
The following are the experimental results of three applications:
[0104] I. The experimental situations of the weak population are shown in the
following
table:
Recovery Overall Average Duration
Microcirculation Total Number
Number Response Rate of Medication
Index (Person)
(Person) (ORR) (%) (Week)
Slight Abnormality 45 42 93.3 2
Moderate
34 30 88.2 4
Abnormality
Severe Abnormality 36 31 86.1 7
It indicates that this product has a good repair and improvement effect on a
variety of
microcirculation disturbance, and the time to response is significantly
shortened.
[0105] II. The experimental results of the population with bone tissue injury
are shown in
the following table:
Recovery
Total Number Recovery Average
Duration of
Type Number
(Person) Rate (%) Medication (Week)
(Person)
Osteoporosis 36 31 86.1 14
24
Date Recue/Date Received 2020-04-27
Osteonecrosis 32 28 87.5 28
Nonunion of
36 34 94.4 10
fracture
Fibrous dysplasia 32 28 87.5 26
Bone cyst 34 31 91.2 26
Chondritis 36 32 88.9 18
It indicates that this product has a good repair and improvement effect on
multiple types of
bone tissue decay, which is superior to that of Embodiment 1.
[01061111. The experimental results of the population with muscle tissue decay
are shown
in the following table:
Recovery
Total Number Average Duration of
Type Number Recovery (%)
(Person) Medication (Week)
(Person)
Recurrent sores 36 31 86.1 13
Unhealed wounds 36 33 91.7 6
Unhealed fistula
36 34 94.4 18
and fistulous tract
Degenerative
32 29 90.6 18
arthritis
Rheumatoid
36 28 77.8 28
arthritis
It indicates that this product has a good repair and improvement effect on
various types of
muscle tissue decay.
[0107] IV. Bone density experiment in the general population:
Date Recue/Date Received 2020-04-27
[0108] On a voluntary basis, 60 subjects with ages between 50 and 65 were
collected and
all had the bone density test in a standard hospital with T values between -
2.5 -- -1, all of
them were mildly low bone density. Among them, 30 patients in the experimental
group
took orally 4-6g of this product, three times a day. In the control group, 30
people were
given calcium carbonate tablets, 1-2g per day. After continuous use for 6
months, recovery
referred to the T value was increased between -1 and 1, maintaining referred
to the T value
did not change, and invalid result referred to the T value was further
reduced. The results
are as follows:
Types n (subjects) Recovery Maintaining Invalid
Control group 30 12 11 7
Experimental group 30 21 9 0
The above experimental results show that the effect of this product is
relatively significant.
Especially in the experimental group, the diet, sleep and defecation of the
subjects are in
good physical conditions, and they are required to continuously take it. The
comprehensive
evaluation is significantly better than that in the control group, so as to
support the transition
of this product from drugs to dietary supplements.
[0109] Embodiment 6: Lumbricus, Pearl, Borneol, White Peony Root, Ligusticum
Wallichii, Polygala Tenuifolia and American Ginseng are added into the raw
materials form
a reinforced formula, with 280-320 units of Angelica Sinensis, 55-65 units of
Panax
Notoginseng, 12-18 units of Carthamus Tinctorius L., 80-100 units of
Lumbricus, 2-5 units
of Pearl, 2-5 units of B orneol, 80-100 units of White Peony Root, 25-35 units
of Ligusticum
Wallichii, 25-35 units of Polygala Tenuifolia and 2-5 units of American
Ginseng. 300 units
of Angelica Sinensis, 60 units of Panax Notoginseng, 15 units of Carthamus
Tinctorius L.,
90 units of Lumbricus, 3 units of Pearl, 3 units of Borneol, 90 units of White
Peony Root,
30 units of Ligusticum Wallichii, 30 units of Polygala Tenuifolia and 3 units
of American
Ginseng are preferred.
[0110] The processing and taking methods, safety and experimental method of
the dietary
supplement described herein are the same as those of Embodiment 4:
The following are the experimental results of three applications:
26
Date Recue/Date Received 2020-04-27
[011111. The experimental situations of the weak population are as follows:
Overall
Total
Microcirculation Recovery Number Response Average Duration
of
Number
Index (Person) Rate (ORR) Medication (Week)
(Person)
(%)
Slight Abnormality 44 42 95.5 2
Moderate
36 33 91.7 4
Abnormality
Severe Abnormality 32 30 93.8 7
It indicates that this product has a good repair and improvement effect on a
variety of
microcirculation disturbance, and the time to response is significantly
shortened.
[0112111. The experimental results of the population with bone tissue injury
are shown in
the following table:
Recovery
Total Number Recovery Average Duration of
Type Number
(Person) Rate (%) Medication (Week)
(Person)
Osteoporosis 36 32 88.9 12
Osteonecrosis 36 31 86.1 26
Nonunion of
32 31 96.6 9
fracture
Fibrous dysplasia 32 30 93.8 24
Bone cyst 36 33 91.7 24
Chondritis 32 29 90.6 16
It indicates that this product has a good repair and improvement effect on
multiple types of
27
Date Recue/Date Received 2020-04-27
bone tissue decay, which is superior to that of Embodiment 1.
[01131111. The experimental results of the population with muscle tissue decay
are shown
in the following table:
Recovery
Total Number Recovery
Rate Average Duration of
Type Number
(Person) C%) Medication (Week)
(Person)
Recurrent sores 36 34 94.4 12
Unhealed wounds 36 35 97.2 3
Unhealed fistula
32 31 96.9 18
and fistulous tract
Degenerative
32 29 90.6 16
arthritis
Rheumatoid
36 29 80.6 26
arthritis
It indicates that this product has a good repair and improvement effect on
various types of
muscle tissue decay.
[0114] IV. Bone density experiment in the general population:
[0115] On a voluntary basis, 60 subjects with ages between 50 and 65 were
collected and
all had the bone density test in a standard hospital with T values between -
2.5 -- -1, all of
them were mildly low bone density. Among them, 30 patients in the experimental
group
took orally 4-6g of this product, three times a day. In the control group, 30
people were
given calcium carbonate tablets, 1-2g per day. After continuous use for 6
months, recovery
referred to the T value was increased between -1 and 1, maintaining referred
to the T value
did not change, and invalid result referred to the T value was further
reduced. The results
are as follows:
28
Date Recue/Date Received 2020-04-27
Types n ( subjects) Recovery Maintaining
Invalid
Control group 30 13 11 6
Experimental group 30 23 7 0
The above experimental results show that the effect of this product is
relatively significant.
Especially in the experimental group, the diet, sleep and defecation of the
subjects are in
good physical conditions, and they are required to continuously take it. The
comprehensive
evaluation is significantly better than that in the control group, so as to
support the transition
of this product from drugs to dietary supplements.
[0116] Embodiment 7: Rhizoma Atractylodis Macrocephaiae, Coix Seed, Chinese
Yam and
Pseudostellaria Heterophylla are added into the raw materials Angelica
Sinensis, Panax
Notoginseng, and Carthamus Tinctorius L., to form a reinforced formula, with
280-320
units of Angelica Sinensis, 55-65 units of Panax Notoginseng, 12-18 units of
Carthamus
Tinctorius L., 80-100 units of Rhizoma Atractylodis Macrocephaiae, 28-32 units
of Coix
Seed, 28-32 units of Chinese Yam, and 2-5 units of Pseudostellaria
Heterophylla.
[0117] 300 units of Angelica Sinensis, 60 units of Panax Notoginseng, 15 units
of
Carthamus Tinctorius L., 90 units of Rhizoma Atractylodis Macrocephaiae, 30
units of
Coix Seed, 30 units of Chinese Yam, and 3 units of Pseudostellaria
Heterophylla are
preferred.
[0118] Introduction to newly added raw materials:
[0119] Rhizoma Atractylodis Macrocephaiae, Atractylodes macrocephala for Latin
name,
with aliases such as Raft Thistle, Winter Atractylodes Macrocephala, Yang
beam, Poplar
Raft, is a perennial herb in Genus Atractylodes in Family Composite. Its
rhizome is used
as medicine.
[0120] Coix Seed (Coix chinensisTod.), also known as Seed of Job's Tears seed
and Six
Millet Seed, is seed of Coix, a plant of Family Grass.
[0121] Chinese Yam, also known as Common Yam Rhizome, Rhizome of Common Yam,
Dioscoreae rhizome, Yam, Roachster, and White Yam, is dry rhizome of Chinese
Yam, a
plant of Family Dioscoreaceae.
29
Date Recue/Date Received 2020-04-27
[0122] Pseudostellaria Heterophylla, Pseudostellaria heterophylla(Miq)Pax for
scientific
name, belongs to Genus Pseudostellaria in Family Caryophyllaceae
(Pseudostellaria
heterophylla(Miq)Pax ex Pax et Hoffm). Its root is used as medicine.
[0123] The processing and taking methods, safety and experimental method of
the dietary
supplement mentioned herein are the same as those of Embodiment 4.
The following are the experimental results of three applications:
[012411. The experimental situations of the weak population are as follows:
Overall
Total Recovery
Response Average Duration of
Microcirculation Index Number Number
Rate (ORR) Medication (Week)
(Person) (Person)
(%)
Slight Abnormality 50 48 96.0 2
Moderate Abnormality 36 34 94.4 4
Severe Abnormality 32 28 87.5 7
It indicates that this product has a good repair and improvement effect on a
variety of
microcirculation disturbance and the time to response is significantly
shortened.
[0125] II. The experimental results of the population with bone tissue injury
are shown in
the following table:
Recovery
Total Number Recovery Average Duration of
Type Number
(Person) Rate (%) Medication (Week)
(Person)
Osteoporosis 36 32 88.9 14
Osteonecrosis 32 28 87.5 28
42 40 95.2 10
Nonunion of
Date Recue/Date Received 2020-04-27
fracture
Fibrous dysplasia 36 32 88.9 26
Bone cyst 34 31 91.2 26
Chondritis 32 29 90.6 18
It indicates that this product has a good repair and improvement effect on
multiple types of
bone tissue decay, which is superior to that of the previous embodiments.
[01261111. The experimental results of the population with muscle tissue decay
are shown
in the following table:
Recovery
Total Number Recovery Rate Average Duration of
Type Number
(Person) (%) Medication (Week)
(Person)
Recurrent sores 36 32 88.9 13
Unhealed wounds 32 30 93.8 6
Unhealed fistula
32 31 96.9 18
and fistulous tract
Degenerative
36 33 91.7 18
arthritis
Rheumatoid
36 29 80.6 28
arthritis
It indicates that this product has a good repair and improvement effect on
various types of
muscle tissue decay.
[0127] IV. Bone density experiment in the general population:
[0128] On a voluntary basis, 60 subjects with ages between 50 and 65 were
collected and
all had the bone density test in a standard hospital with T values between -
2.5 -- -1, all of
31
Date Recue/Date Received 2020-04-27
them were mildly low bone density. Among them, 30 patients in the experimental
group
took orally 4-6g of this product, three times a day. In the control group, 30
people were
given calcium carbonate tablets, 1-2g per day. After continuous use for 6
months, recovery
referred to the T value was increased between -1 and 1, maintaining referred
to the T value
did not change, and invalid result referred to the T value was further
reduced. The results
are as follows:
Types n (subjects) Recovery Maintaining Invalid
Control group 30 14 10 6
Experimental group 30 22 8 0
The above experimental results show that the effect of this product is
relatively significant.
Especially in the experimental group, the diet, sleep and defecation of the
subjects are in
good physical conditions, and they are required to continuously take it. The
comprehensive
evaluation is significantly better than that in the control group, so as to
support the transition
of this product from drugs to dietary supplements.
[0129] Embodiment 8: Lumbricus, Pearl, Borneol, Rhizoma Atractylodis
Macrocephaiae,
Coix Seed, Chinese Yam and Pseudostellaria Heterophylla are added to the
aforesaid raw
materials, form a form a reinforced formula, with 180-220 units of Angelica
Sinensis, 55-
65 units of Panax Notoginseng, 12-18 units of Carthamus Tinctorius L., 80-100
units of
Lumbricus, 2-5 units of Pearl, 2-5 units of Borneol, 80-100 units of Rhizoma
Atractylodis
Macrocephaiae, 28-32 units of Coix Seed, 28-32 units of Chinese Yam, and 2-5
units of
Pseudostellaria Heterophylla.
[0130] 200 units of Angelica Sinensis, 60 units of Panax Notoginseng, 15 units
of
Carthamus Tinctorius L., 90 units of Lumbricus, 3 units of Pearl, 3 units of
Borneol, 90
units of Rhizoma Atractylodis Macrocephaiae, 30 units of Coix Seed, 30 units
of Chinese
Yam, and 3 units of Pseudostellaria Heterophylla are preferred.
[0131] The processing and taking methods, safety and experimental method of
the dietary
supplement mentioned herein are the same as those of Embodiment 4. The
following are
the experimental results of three applications:
32
Date Recue/Date Received 2020-04-27
[0132] I. The experimental situations of the weak population are as follows:
Total Recovery Overall Average Duration
Microcirculation
Number Number Response Rate of
Medication
Index
(Person) (Person) (ORR) (%) (Week)
Slight Abnormality 56 54 96.4 2
Moderate
42 40 95.2 4
Abnormality
Severe Abnormality 32 29 90.6 7
It indicates that this product has a good repair and improvement effect on a
variety of
microcirculation disturbance, and the time to response is significantly
shortened.
[0133] II. The experimental results of the population with bone tissue injury
are shown in
the following table:
Recovery
Total Number Recovery Average
Duration of
Type Number
(Person) Rate (%) Medication (Week)
(Person)
Osteoporosis 36 33 91.6 14
Osteonecrosis 32 29 90.6 28
Nonunion of
43 42 97.7 10
fracture
Fibrous dysplasia 36 33 91.6 26
Bone cyst 36 33 91.6 26
Chondritis 38 35 92.1 18
It indicates that this product has a good repair and improvement effect on
multiple types of
bone tissue decay, which is superior to that of the previous embodiments.
33
Date Recue/Date Received 2020-04-27
[0134] III. The experimental results of the population with muscle tissue
decay are shown
in the following table:
Recovery
Total Number Recovery Rate Average Duration of
Type Number
(Person) (%) Medication (Week)
(Person)
Recurrent sores 38 35 92.1 13
Unhealed wounds 32 31 96.9 6
Unhealed fistula
36 35 97.2 18
and fistulous tract
Degenerative
36 33 91.7 18
arthritis
Rheumatoid
36 30 83.3 28
arthritis
It indicates that this product has a good repair and improvement effect on
various types of
muscle tissue decay.
[0135] IV. Bone density experiment in the general population:
[0136] On a voluntary basis, 60 subjects with ages between 50 and 65 were
collected and
all had the bone density test in a standard hospital with T values between -
2.5 -- -1, all of
them were mildly low bone density. Among them, 30 patients in the experimental
group
took orally 4-6g of this product, three times a day. In the control group, 30
people were
given calcium carbonate tablets, 1-2g per day. After continuous use for 6
months, recovery
referred to the T value was increased between -1 and 1, maintaining referred
to the T value
did not change, and invalid result referred to the T value was further
reduced. The results
are as follows:
34
Date Recue/Date Received 2020-04-27
Types n ( subjects) Recovery Maintaining
Invalid
Control group 30 13 10 7
Experimental group 30 24 6 0
The above experimental results show that the effect of this product is
relatively significant.
Especially in the experimental group, the diet, sleep and defecation of the
subjects are in
good physical conditions, and they are required to continuously take it. The
comprehensive
evaluation is significantly better than that in the control group, so as to
support the transition
of this product from drugs to dietary supplements.
[0137] Embodiment 9: Astragalus Membranaceus, Psoralen, Polygala Tenuifolia
and Radix
Glycyrrhizae are added to the raw materials Angelica Sinensis, Panax
Notoginseng and
Carthamus Tinctorius L., to form a reinforced formula, with 180-220 units of
Angelica
Sinensis, 55-65 units of Panax Notoginseng, 12-18 units of Carthamus
Tinctorius L., 80-
100 units of Astragalus Membranaceus, 28-32 units of Psoralen, 28-32 units of
Polygala
Tenuifolia and 2-5 units of Radix Glycyrrhizae.
[0138] 200 units of Angelica Sinensis, 60 units of Panax Notoginseng, 15 units
of
Carthamus Tinctorius L., 90 units of Astragalus Membranaceus, 30 units of
Psoralen, 30
units of Polygala Tenuifolia and 3 units of Radix Glycyrrhizae are preferred
[0139] Introduction to newly added raw materials:
[0140] Astragalus Membranaceus (stragalus membranaceus (Fisch.) Bunge.), also
known
as Radix Astragali, is a perennial herb of Genus Astragalus of Order Rosaceae
of Family
Leguminosae.
[0141] Psoralea (Scientific name: Psoralea corylifoliaLinn.), also known as
Fructus
Psoraleae, is an annual erect herb of Order Rosaceae of Family Leguminosae.
Its fruit is
used as medicine.
[0142] Radix Glycyrrhizae (Scientific name: Glycyrrhiza uralensis Fisch), also
known as
Sweet Grass and Sweet Root, is a perennial herb of Order Glycyrrhiza of Family
Leguminosae.
Date Recue/Date Received 2020-04-27
[0143] The processing and taking methods, safety and experimental method of
the dietary
supplement mentioned herein are the same as those of Embodiment 4.
The following are the experimental results of three applications:
[014411. The experimental situations of the weak population are as follows:
Total Recovery Overall Average Duration
Microcirculation Index Number Number Response Rate of
Medication
(Person) (Person) (ORR) (%) (Week)
Slight Abnormality 65 61 93.8 2
Moderate Abnormality 54 49 90.7 4
Severe Abnormality 36 32 88.9 7
It indicates that this product has a good repair and improvement effect on a
variety of
microcirculation disturbance.
[0145] II. The experimental results of the population with bone tissue injury
are shown in
the following table:
Total Recovery
Recovery Rate Average Duration of
Type Number Number
(%) Medication (Week)
(Person) (Person)
Osteoporosis 38 34 89.5 14
Osteonecrosis 36 32 88.9 28
Nonunion of
39 38 97.4 10
fracture
Fibrous dysplasia 36 33 91.7 26
Bone cyst 38 35 92.1 26
Chondritis 36 33 91.7 18
36
Date Recue/Date Received 2020-04-27
It indicates that this product has a good repair and improvement effect on
multiple types of
bone tissue decay, which is superior to that of Embodiment 1.
[01461111. The experimental results of the population with muscle tissue decay
are shown
in the following table:
Recovery
Total Number Recovery Rate Average Duration
of
Type Number
(Person) (%) Medication (Week)
(Person)
Recurrent sores 46 41 89.1 13
Unhealed wounds 42 39 92.9 6
Unhealed fistula
44 42 95.5 18
and fistulous tract
Degenerative
36 33 91.7 18
arthritis
Rheumatoid
46 41 89.1 28
arthritis
It indicates that this product has a good repair and improvement effect on
various types of
muscle tissue decay.
[0147] IV. Bone density experiment in the general population:
[0148] On a voluntary basis, 60 subjects with ages between 50 and 65 were
collected and
all had the bone density test in a standard hospital with T values between -
2.5 -- -1, all of
them were mildly low bone density. Among them, 30 patients in the experimental
group
took orally 4-6g of this product, three times a day. In the control group, 30
people were
given calcium carbonate tablets, 1-2g per day. After continuous use for 6
months, recovery
referred to the T value was increased between -1 and 1, maintaining referred
to the T value
did not change, and invalid result referred to the T value was further
reduced. The results
are as follows:
37
Date Recue/Date Received 2020-04-27
Types n (subjects) Recovery Maintaining Invalid
Control group 30 12 11 7
Experimental group 30 23 6 1
The above experimental results show that the effect of this product is
relatively significant.
Especially in the experimental group, the diet, sleep and defecation of the
subjects are in
good physical conditions, and they are required to continuously take it. The
comprehensive
evaluation is significantly better than that in the control group, so as to
support the transition
of this product from drugs to dietary supplements.
[0149] Embodiment 10: Lumbricus, Pearl, Borneol, Astragalus Membranaceus,
Psoralen,
Polygala Tenuifolia and Radix Glycyrrhizae are added into the aforesaid raw
materials
Angelica Sinensis, Panax Notoginseng and Carthamus Tinctorius L., to a form a
reinforced
formula, with 180-220 units of Angelica Sinensis, 55-65 units of Panax
Notoginseng, 12-
18 units of Carthamus Tinctorius L., 80-100 units of Lumbricus, 2-5 units of
Pearl, 2-5
units of Borneol, 80-100 units of Astragalus Membranaceus, 28-32 units of
Psoralen, 28-
32 units of Polygala Tenuifolia, and 2-5 units of Radix Glycyrrhizae.
[0150] 200 units of Angelica Sinensis, 60 units of Panax Notoginseng, 15 units
of
Carthamus Tinctorius L., 90 units of Lumbricus, 3 units of Pearl, 3 units of
Borneol, 90
units of Astragalus Membranaceus, 30 units of Psoralen, 30 units of Polygala
Tenuifolia,
and 3 units of Radix Glycyrrhizae are preferred.
[0151] The processing method of the dietary supplement mentioned herein is to
powder all
raw materials, screen the powder with more 80 meshes, and then made into
decoction,
powder, pill, tablet or capsule.
[0152] The usage of the dietary supplement is to orally take 5-12g every time,
three times
a day, for adults.
[0153] The processing and taking methods, safety and experimental method of
the dietary
supplement mentioned herein are the same as those of Embodiment 4.
The following are the experimental results of three applications:
38
Date Recue/Date Received 2020-04-27
[015411. The experimental situations of the weak population are as follows:
Recovery Overall Average Duration
Microcirculation Total Number
Number Response Rate of Medication
Index (Person)
(Person) (ORR) (%) (Week)
Slight Abnormality 63 60 95.2 2
Moderate
56 52 92.9 4
Abnormality
Severe Abnormality 38 34 89.5 7
It indicates that this product has a good repair and improvement effect on a
variety of
microcirculation disturbance.
[0155] II. The experimental results of the population with bone tissue injury
are shown in
the following table:
Total Recovery
Recovery Rate Average Duration of
Type Number Number
(%) Medication (Week)
(Person) (Person)
Osteoporosis 41 38 92.7 14
Osteonecrosis 36 33 91.7 28
Nonunion of
52 51 98.1 10
fracture
Fibrous dysplasia 36 33 91.7 26
Bone cyst 40 37 92.5 26
Chondritis 38 35 92.1 18
It indicates that this product has a good repair and improvement effect on
multiple types of
bone tissue decay, which is superior to that of Embodiment 1.
39
Date Recue/Date Received 2020-04-27
[0156] III. The experimental results of the population with muscle tissue
decay are shown
in the following table:
Recovery
Total Number Recovery Rate .. Average Duration of
Type Number
(Person) (%) Medication (Week)
(Person)
Recurrent sores 49 45 91.8 13
Unhealed wounds 42 40 95.2 6
Unhealed fistula
48 46 95.8 18
and fistulous tract
Degenerative
36 34 94.4 18
arthritis
Rheumatoid
48 44 91.7 28
arthritis
It indicates that this product has a good repair and improvement effect on
various types of
muscle tissue decay.
[0157] IV. Bone density experiment in the general population:
[0158] On a voluntary basis, 60 subjects with ages between 50 and 65 were
collected and
all had the bone density test in a standard hospital with T values between -
2.5 -- -1, all of
them were mildly low bone density. Among them, 30 patients in the experimental
group
took orally 4-6g of this product, three times a day. In the control group, 30
people were
given calcium carbonate tablets, 1-2g per day. After continuous use for 6
months, recovery
referred to the T value was increased between -1 and 1, maintaining referred
to the T value
did not change, and invalid result referred to the T value was further
reduced. The results
are as follows:
Date Recue/Date Received 2020-04-27
Types n ( subjects) Recovery Maintaining
Invalid
Control group 30 11 12 7
Experimental group 30 25 5 0
The above experimental results show that the effect of this product is
relatively significant.
Especially in the experimental group, the diet, sleep and defecation of the
subjects are in
good physical conditions, and they are required to continuously take it. The
comprehensive
evaluation is significantly better than that in the control group, so as to
support the transition
of this product from drugs to dietary supplements.
[0159] Embodiment 11: Achyranthes Bidentata, Sealwort, White Peony Root and
Eurycoma Longifolia are added into the aforesaid raw materials Angelica
Sinensis, Panax
Notoginseng and Carthamus Tinctorius L., to form a reinforced formula, with
180-220 units
of Angelica Sinensis, 55-65 units of Panax Notoginseng, 12-18 units of
Carthamus
Tinctorius L., 28-32 units of Achyranthes Bidentata, 28-32 units of Sealwort,
80-100 units
of White Peony Root, and 2-5 units of Eurycoma Longifolia.
200 units of Angelica Sinensis, 60 units of Panax Notoginseng, 15 units of
Carthamus
Tinctorius L., 30 units of Achyranthes Bidentata, 30 units of Sealwort, 90
units of White
Peony Root, and 3 units of Eurycoma Longifolia are preferred.
[0160] Introduction to newly added raw materials:
[0161] Achyranthes Bidentata (Latin name: Achyranthes bidentata Blume.), also
known as
Hyssop, is a perennial herb of Genus Hyssop of Family Amaranthaceae.
[0162] Achyranthes Bidentata (Scientific name: Polygonatum sibiricum), also
known as
Chicken Head Yellow Essence, Yellow Chicken Vegetable, and Pen Tube Vegetable.
[0163] Eurycoma Longifolia is a wild shrub in tropical rain forests around the
equator in
Southeast Asia. It belongs to Genus Euryalium of Family Simarubaceae of
Sapindales
Order. Its root has various effects.
[0164] The processing and taking methods, safety and experimental method of
the dietary
supplement mentioned herein are the same as those of Embodiment 4. The
following are
41
Date Recue/Date Received 2020-04-27
the experimental results of three applications:
[016511. The experimental situations of the weak population are as follows:
Recovery Overall Average Duration
Microcirculation Total Number
Number Response Rate of Medication
Index (Person)
(Person) (ORR) (%) (Week)
Slight Abnormality 50 47 94.0 2
Moderate
44 40 90.9 4
Abnormality
Severe Abnormality 38 33 86.8 7
It indicates that this product has a good repair and improvement effect on a
variety of
microcirculation disturbance.
[0166] II. The experimental results of the population with bone tissue injury
are shown in
the following table:
Recovery
Total Number Recovery Average Duration of
Type Number
(Person) Rate (%) Medication (Week)
(Person)
Osteoporosis 44 39 88.6 14
Osteonecrosis 36 32 88.9 28
Nonunion of
50 48 96.0 10
fracture
Fibrous dysplasia 36 32 88.9 26
Bone cyst 39 36 92.3 26
Chondritis 38 35 92.1 18
42
Date Recue/Date Received 2020-04-27
It indicates that this product has a good repair and improvement effect on
various types of
bone tissue decay.
[01671111. The experimental results of the population with muscle tissue decay
are shown
in the following table:
Recovery
Total Number Recovery Rate Average Duration
of
Type Number
(Person) (%) Medication (Week)
(Person)
Recurrent sores 46 41 89.1 13
Unhealed wounds 44 42 95.5 6
Unhealed fistula
36 35 97.2 18
and fistulous tract
Degenerative
42 40 95.2 18
arthritis
Rheumatoid
36 30 83.3 28
arthritis
It indicates that this product has a good repair and improvement effect on
various types of
muscle tissue decay.
[0168] IV. Bone density experiment in the general population:
[0169] On a voluntary basis, 60 subjects with ages between 50 and 65 were
collected and
all had the bone density test in a standard hospital with T values between -
2.5 -- -1, all of
them were mildly low bone density. Among them, 30 patients in the experimental
group
took orally 4-6g of this product, three times a day. In the control group, 30
people were
given calcium carbonate tablets, 1-2g per day. After continuous use for 6
months, recovery
referred to the T value was increased between -1 and 1, maintaining referred
to the T value
did not change, and invalid result referred to the T value was further
reduced. The results
are as follows:
43
Date Recue/Date Received 2020-04-27
Types n (subjects) Recovery Maintaining
Invalid
Control group 30 12 11 7
Experimental group 30 23 6 1
The above experimental results show that the effect of this product is
relatively significant.
Especially in the experimental group, the diet, sleep and defecation of the
subjects are in
good physical conditions, and they are required to continuously take it. The
comprehensive
evaluation is significantly better than that in the control group, so as to
support the transition
of this product from drugs to dietary supplements.
[0170] Embodiment 12: Lumbricus, Pearl, Borneol, Achyranthes Bidentata,
Sealwort,
White Peony Root and Eurycoma Longifolia are added into the raw materials
Angelica
Sinensis, Panax Notoginseng and Carthamus Tinctorius L., to form a reinforced
formula,
with 180-220 units of Angelica Sinensis, 55-65 units of Panax Notoginseng, 12-
18 units of
Carthamus Tinctorius L., 80-100 units of Lumbricus, 2-5 units of Pearl, 2-5
units of Borneol,
28-32 units of Achyranthes Bidentata, 28-32 units of Sealwort, 80-100 units of
White
Peony Root, and 2-5 units of Eurycoma Longifolia.
200 units of Angelica Sinensis, 60 units of Panax Notoginseng, 15 units of
Carthamus
Tinctorius L., 90 units of Lumbricus, 3 units of Pearl, 3 units of Borneol, 30
units of
Achyranthes Bidentata, 30 units of Sealwort, 90 units of White Peony Root, and
3 units of
Eurycoma Longifolia are preferred.
[0171]The processing and taking methods, safety and experimental method of the
dietary
supplement mentioned herein are the same as those of Embodiment 4.
The following are the experimental results of three applications:
[0172] I. The experimental situations of the weak population are as follows:
Recovery Overall Average Duration
Microcirculat ion Total Number
Number Response Rate of Medication
Index (Person)
(Person) (ORR) (%) (Week)
44
Date Recue/Date Received 2020-04-27
Slight Abnormality 56 54 96.4 2
Moderate
54 51 94.4 4
Abnormality
Severe Abnormality 42 38 90.5 7
It indicates that this product has a good repair and improvement effect on a
variety of
microcirculation disturbance.
[0173] II. The experimental results of the population with bone tissue injury
are shown in
the following table:
Recovery
Total Number Recovery Average Duration of
Type Number
(Person) Rate (%) Medication (Week)
(Person)
Osteoporosis 48 44 91.7 14
Osteonecrosis 38 36 94.7 28
Nonunion of
62 61 98.4 10
fracture
Fibrous dysplasia 36 33 91.6 26
Bone cyst 42 40 95.2 26
Chondritis 38 36 94.7 18
It indicates that this product has a good repair and improvement effect on
various types of
bone tissue decay.
[01741111. The experimental results of the population with muscle tissue decay
are shown
in the following table:
Date Recue/Date Received 2020-04-27
Recovery
Total Number Recovery Rate Average Duration of
Type Number
(Person) (%) Medication (Week)
(Person)
Recurrent sores 46 43 93.4 13
Unhealed wounds 48 47 97.9 6
Unhealed fistula
46 45 97.8 18
and fistulous tract
Degenerative
46 44 95.7 18
arthritis
Rheumatoid
38 33 86.8 28
arthritis
It indicates that this product has a good repair and improvement effect on
various types of
muscle tissue decay.
[0175] IV. Bone density experiment in the general population:
[0176] On a voluntary basis, 60 subjects with ages between 50 and 65 were
collected and
all had the bone density test in a standard hospital with T values between -
2.5 -- -1, all of
them were mildly low bone density. Among them, 30 patients in the experimental
group
took orally 4-6g of this product, three times a day. In the control group, 30
people were
given calcium carbonate tablets, 1-2g per day. After continuous use for 6
months, recovery
referred to the T value was increased between -1 and 1, maintaining referred
to the T value
did not change, and invalid result referred to the T value was further
reduced. The results
are as follows:
Types n (subjects) Recovery Maintaining Invalid
Control group 30 12 11 7
Experimental group 30 24 6 0
46
Date Recue/Date Received 2020-04-27
The above experimental results show that the effect of this product is
relatively significant.
Especially in the experimental group, the diet, sleep and defecation of the
subjects are in
good physical conditions, and they are required to continuously take it. The
comprehensive
evaluation is significantly better than that in the control group, so as to
support the transition
of this product from drugs to dietary supplements.
[0177] Embodiment 13: Ligusticum Wallichii, Prepared Rehmannia Glutinosa,
Eucommia
Ulmoides and Rhodiola Rosea are added into the raw materials Angelica
Sinensis, Panax
Notoginseng and Carthamus Tinctorius L., to forma reinforced formula, with 180-
220 units
of Angelica Sinensis, 55-65 units of Panax Notoginseng, 12-18 units of
Carthamus
Tinctorius L., 80-100 units of Ligusticum Wallichii, 28-32 units of Prepared
Rehmannia
Glutinosa, 28-32 units of Eucommia Ulmoides and 2-5 units of Rhodiola Rosea.
200 units of Angelica Sinensis, 60 units of Panax Notoginseng, 15 units of
Carthamus
Tinctorius L., 90 units of Ligusticum Wallichii, 30 units of Prepared
Rehmannia Glutinosa,
30 units of Eucommia Ulmoides and 3 units of Rhodiola Rosea are preferred.
[0178] Introduction to newly added raw materials:
Prepared Rehmannia Glutinosa is the earthnut of Rehmannia Glutinosa (Latin
name:
Chinese Foxglove), also known as Prepared Rehmannia or Foxglove.
[0179] Eucommia Ulmoides (Scientific name: Eucommia ulmoides Oliver), also
known as
Bakelite, is a plant of Family Eucommiaceae. Its dry bark is used as medicine.
[0180] Rhodiola Rosea (Scientific name: Rhodiola rosea L.), with the alias of
Rose
Rhodiola Rosea and Saul Mapur (Tibetan name), is a perennial herb of Family
Crassulaceae
of Order Rrosaceae.
[0181] The processing and taking methods, safety and experimental method of
the dietary
supplement mentioned herein are the same as those of Embodiment 4.
The following are the experimental results of three applications:
[0182] I. The experimental situations of the weak population are as follows:
47
Date Recue/Date Received 2020-04-27
Total Overall Average
Duration
Microcirculation Recovery
Number Response Rate of Medication
Index Number (Person)
(Person) (ORR) (%) (Week)
Slight Abnormality 55 53 96.4 3
Moderate
44 41 93.2 5
Abnormality
Severe Abnormality 39 34 87.2 8
It indicates that this product has a good repair and improvement effect on a
variety of
microcirculation disturbance.
[0183] II. The experimental results of the population with bone tissue injury
are shown in
the following table:
Recovery
Total Number Recovery Average
Duration of
Type Number
(Person) Rate (%) Medication (Week)
(Person)
Osteoporosis 45 41 91.1 14
Osteonecrosis 40 37 92.5 28
Nonunion of
46 45 97.8 10
fracture
Fibrous dysplasia 42 39 92.9 26
Bone cyst 38 36 94.7 26
Chondritis 36 34 94.4 18
It indicates that this product has a good repair and improvement effect on
multiple types of
bone tissue decay, which is superior to that of Embodiment 1.
[0184] III. The experimental results of the population with muscle tissue
decay are shown
48
Date Recue/Date Received 2020-04-27
in the following table:
Recovery
Total Number Recovery Rate Average Duration of
Type Number
(Person) (%) Medication (Week)
(Person)
Recurrent sores 56 52 92.9 13
Unhealed wounds 54 51 94.4 6
Unhealed fistula
36 35 97.2 18
and fistulous tract
Degenerative
42 40 95.2 18
arthritis
Rheumatoid
46 40 87.0 28
arthritis
It indicates that this product has a good repair and improvement effect on
various types of
muscle tissue decay.
[0185] IV. Bone density experiment in the general population:
[0186] On a voluntary basis, 60 subjects with ages between 50 and 65 were
collected and
all had the bone density test in a standard hospital with T values between -
2.5 -- -1, all of
them were mildly low bone density. Among them, 30 patients in the experimental
group
took orally 4-6g of this product, three times a day. In the control group, 30
people were
given calcium carbonate tablets, 1-2g per day. After continuous use for 6
months, recovery
referred to the T value was increased between -1 and 1, maintaining referred
to the T value
did not change, and invalid result referred to the T value was further
reduced. The results
are as follows:
Types n (subjects) Recovery Maintaining Invalid
Control group 30 14 10 6
Experimental group 30 25 4 1
49
Date Recue/Date Received 2020-04-27
The above experimental results show that the effect of this product is
relatively significant.
Especially in the experimental group, the diet, sleep and defecation of the
subjects are in
good physical conditions, and they are required to continuously take it. The
comprehensive
evaluation is significantly better than that in the control group, so as to
support the transition
of this product from drugs to dietary supplements.
[0187] Embodiment 14: Lumbricus, Pearl, Bomeol, Ligusticum Wallichii, Prepared
Rehmannia Glutinosa, Eucommia Ulmoides and Rhodiola Rosea are added into the
aforesaid raw materials, to form a reinforced formula with 180-220 units of
Angelica
Sinensis, 55-65 units of Panax Notoginseng, 12-18 units of Carthamus
Tinctorius L., 80-
100 units of Lumbricus, 2-5 units of Pearl, 2-5 units of Borneol, 80-100 units
of Ligusticum
Wallichii, 28-32 units of Prepared Rehmannia Glutinosa, 28-32 units of
Eucommia
Ulmoides and 2-5 units of Rhodiola Rosea.
[0188] 200 units of Angelica Sinensis, 60 units of Panax Notoginseng, 15 units
of
Carthamus Tinctorius L., 90 units of Lumbricus, 3 units of Pearl, 3 units of
Borneol, 90
units of Ligusticum Wallichii, 30 units of Prepared Rehmannia Glutinosa, 30
units of
Eucommia Ulmoides and 3 units of Rhodiola Rosea are preferred.
[0189] The processing and taking methods, safety and experimental method of
the dietary
supplement mentioned herein are the same as those of Embodiment 4.
The following are the experimental results of the three applications:
[0190] I. The experimental situations of the weak population are as follows:
Total Recovery Overall Average Duration
M icroci rculat ion
Number Number Response Rate of Medication
Index
(Person) (Person) (ORR) (%) (Week)
Slight Abnormality 58 57 98.3 3
Moderate
54 52 96.3 5
Abnormality
Severe Abnormality 38 34 89.5 8
Date Recue/Date Received 2020-04-27
It indicates that this product has a good repair and improvement effect on a
variety of
microcirculation disturbance.
[0191] II. The experimental results of the population with bone tissue injury
are shown in
the following table:
Recovery
Total Number Recovery Average Duration
of
Type Number
(Person) Rate (%) Medication (Week)
(Person)
Osteoporosis 55 52 94.5 14
Osteonecrosis 60 57 95.0 28
Nonunion of
66 65 98.5 10
fracture
Fibrous dysplasia 52 49 94.2 26
Bone cyst 49 47 95.9 26
Chondritis 46 44 95.6 18
It indicates that this product has a good repair and improvement effect on
multiple types of
bone tissue decay, which is superior to that of Embodiment 1.
[01921111. The experimental results of the population with muscle tissue decay
are shown
in the following table:
Recovery
Total Number Recovery Rate Average Duration
of
Type Number
(Person) (%) Medication (Week)
(Person)
Recurrent sores 55 52 94.5 13
Unhealed wounds 58 56 96.6 6
51
Date Recue/Date Received 2020-04-27
Unhealed fistula
62 61 98.4 18
and fistulous tract
Degenerative
52 50 96.2 18
arthritis
Rheumatoid
48 43 89.6 28
arthritis
It indicates that this product has a good repair and improvement effect on
various types of
muscle tissue decay.
[0193] IV. Bone density experiment in the general population:
[0194] On a voluntary basis, 60 subjects with ages between 50 and 65 were
collected and
all had the bone density test in a standard hospital with T values between -
2.5 -- -1, all of
them were mildly low bone density. Among them, 30 patients in the experimental
group
took orally 4-6g of this product, three times a day. In the control group, 30
people were
given calcium carbonate tablets, 1-2g per day. After continuous use for 6
months, recovery
referred to the T value was increased between -1 and 1, maintaining referred
to the T value
did not change, and invalid result referred to the T value was further
reduced. The results
are as follows:
Types n (subjects) Recovery Maintaining Invalid
Control group 30 13 9 8
Experimental group 30 26 4 0
The above experimental results show that the effect of this product is
relatively significant.
Especially in the experimental group, the diet, sleep and defecation of the
subjects are in
good physical conditions, and they are required to continuously take it. The
comprehensive
evaluation is significantly better than that in the control group, so as to
support the transition
of this product from drugs to dietary supplements.
52
Date Recue/Date Received 2020-04-27
